Daniel K. Spiegelman
Independent Member of Board of Directors
Mr. Spiegelman was senior vice president and chief financial officer of CV Therapeutics, Inc., a publicly traded biopharmaceutical company that is focused on applying molecular cardiology to the discovery, development, and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. He joined CV Therapeutics in January 1998 as vice president and CFO. Previously, he was employed by Genentech, Inc., where he held a number of positions in the treasury department, including treasurer. Mr. Spiegelman currently serves as a member of the board of directors of Anthera Pharmaceuticals, Inc., a biopharmaceutical company, Omeros Corporation, a biopharmaceutical company, Oncothyreon, Inc., a biotechnology company, and Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company. He previously served as a director for Xcyte Therapies, Inc. before its merger with Cyclacel in March 2006. Mr. Spiegelman holds a B.A. in economics from Stanford University and a M.B.A. from Stanford Graduate School of Business.